January 8, 2010 — Patients with pernicious anemia have significantly higher risks for hip fracture, research shows.

Compared to age- and sex-matched controls, patients with pernicious anemia had a 73% greater risk of hip fracture (3.4 vs. 2.0 hip fractures/1000 person-years of follow-up). The elevated risk was even greater with newly diagnosed pernicious anemia (HR, 2.63).

January 8, 2010 — Thoracoabdominal calcifications on radiography predict cardiovascular and total mortality, according to the results of an 18-year follow-up study reported online in the December 15, 2009, issue of Diabetes Care.

Sopherion Therapeutics, LLC, a bio-pharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it has received Fast Track Designation from the US Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet) for first-line therapy of HER2 positive metastatic breast cancer. Treatment with Myocet has already shown a reduced level of cardiotoxicity as compared to traditional doxorubicin.

Stride Arcolabs

Work as Head / Manager – BD (International Operations)

NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (NIPER), 2010